Prenetics Global (NASDAQ:PRE – Get Rating) is one of 726 public companies in the “Holding & other investment offices” industry, but how does it contrast to its rivals? We will compare Prenetics Global to related businesses based on the strength of its valuation, dividends, risk, analyst recommendations, institutional ownership, earnings and profitability.
Valuation & Earnings
This table compares Prenetics Global and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Prenetics Global | $275.76 million | -$190.45 million | -0.17 |
| Prenetics Global Competitors | $1.61 billion | -$5.96 million | -7.57 |
Prenetics Global’s rivals have higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
Analyst Recommendations
This is a summary of recent ratings and target prices for Prenetics Global and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 0 | 0 | 2 | 0 | 3.00 |
| Prenetics Global Competitors | 115 | 592 | 890 | 15 | 2.50 |
Prenetics Global currently has a consensus price target of $7.00, suggesting a potential upside of 677.78%. As a group, “Holding & other investment offices” companies have a potential upside of 73.02%. Given Prenetics Global’s stronger consensus rating and higher possible upside, analysts plainly believe Prenetics Global is more favorable than its rivals.
Volatility & Risk
Prenetics Global has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500. Comparatively, Prenetics Global’s rivals have a beta of 0.04, indicating that their average share price is 96% less volatile than the S&P 500.
Profitability
This table compares Prenetics Global and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -69.07% | -0.09% | -0.05% |
| Prenetics Global Competitors | -48.76% | -66.88% | -1.61% |
Summary
Prenetics Global rivals beat Prenetics Global on 7 of the 13 factors compared.
Prenetics Global Company Profile
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
